natgillin/translations-raw huggingface dataset:
Frequency not known (frequency cannot be estimated from the available data) involuntary muscle movements (muscle contraction involuntary).
Učestalost nepoznata (učestalost se ne može procijeniti iz dostupnih podataka) nevoljni mišićni pokreti (nevoljne mišićne kontrakcije).
Frequency not known (frequency cannot be estimated from the available data): suicidal thoughts or behaviour.
Učestalost nepoznata (učestalost se ne može procijeniti iz dostupnih podataka): suicidalne misli ili suicidalno ponašanje.
Frequency not known*
Nepoznata učestalost
Frequency not known:
Nepoznata učestalost :
Frequency not known: blistering of skin (bullous pemphigoid)
Učestalost nije poznata: stvaranje mjehura na koži (bulozni pemfigoid)
Frequency not known: hallucination, confusion (especially in patients with a history of these symptoms); decreased level of sodium in blood; decreased level of magnesium in blood, rash, possibly with pain in the joints.
Nepoznata učestalost: halucinacije, smetenost (pogotovo kod bolesnika koji su već imali te simptome), smanjenje razine natrija u krvi; smanjenje razine magnezija u krvi, osip, moguće praćen boli u zglobovima.
Frequency not known: hallucination, confusion (especially in patients with a history of these symptoms); decreased level of sodium in blood; decreased level of magnesium in blood.
Nepoznata učestalost: halucinacije, smetenost (pogotovo kod bolesnika koji su već imali te simptome), smanjenje razine natrija u krvi; smanjenje razine magnezija u krvi.
Frequency not known: hepatotoxicity (mostly described as transaminase increased)
hepatotoksičnost (većinom opisana kao povišene transaminaze)
Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease
Nepoznata učestalost: problemi s bubrezima (ponekad zahtijevaju dijalizu), povraćanje, bol u zglobovima, bol u mišićima, bol u leđima, intersticijska bolest pluća
Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease
Učestalost nepoznata: tegobe s bubrezima (ponekad zahtijevaju dijalizu), povraćanje, bol u zglobovima, bol u mišićima, bol u leđima, intersticijska bolest pluća
Frequency not known: loss of consciousness, stop in breathing, convulsion (fits)
Nepoznata učestalost: gubitak svijesti, prestanak disanja, konvulzije (napadaji)
Frequency not known: Transient neurological symptoms (i.e. hypoesthesia, muscle spasm, paraesthesia, difficulty in walking, musculoskeletal stiffness) that may mimic multiple sclerosis exacerbations*
Učestalost nije poznata: Prolazni neurološki simptomi (primjerice, hipoestezija, spazam mišića, parestezija, poteškoće u hodanju, ukočenost mišića i kostiju) koji mogu imitirati simptome pogoršanja multiple skleroze
Frequency not known:Superinfection of skin lesions*.
Nepoznata učestalost: Superinfekcija kožnih lezija.
Frequency of administration
Učestalost davanja
Frequency of adverse reaction
Učestalost nuspojave
Frequency of adverse reactions
Učestalost nuspojava
Frequency of adverse reactions
Učestalost nuspojave
Frequency of adverse reactions
Učestalosti nuspojava
Frequency of Adverse Reactions (ADRs) in clinical studies with Flebogamma DIF 100 mg/ml
Učestalost nuspojava u kliničkim ispitivanjima s lijekom Flebogamma DIF 100 mg/ml
Frequency of Adverse Reactions (ADRs) in clinical studies with Flebogamma DIF 50 mg/ml
Učestalost nuspojava u kliničkim ispitivanjima s lijekom Flebogamma DIF 50 mg/ml
Frequency of Adverse Reactions (ADRs) in clinical studies with KIOVIG
Učestalost nuspojava – u kliničkim ispitivanjima s lijekom KIOVIG
Frequency of Adverse Reactions (ADRs) with HyQvia
Učestalost nuspojava uz lijek HyQvia
Frequency of Adverse Reactions (ARs) in clinical studies and post-marketing experience with Respreeza
Učestalost nuspojava u kliničkim ispitivanjima i iskustvu nakon stavljanja Respreeze na tržište
Frequency of Adverse Reactions (ARs) in clinical studies with Hizentra
Učestalost nuspojava u kliničkim ispitivanjima s Hizentrom
Frequency of adverse reactions by treatment regimen Saxagliptin with metformin1
Učestalost nuspojava prema režimu liječenja Saksagliptin s metforminom1
Frequency of Adverse reactions in clinical trials and postmarketing surveillance is reported hereunder.
Učestalost nuspojava u kliničkim ispitivanjima i istraživanjima nakon stavljanja cjepiva u promet je navedena ispod.
Frequency of Adverse reactions in clinical trials and postmarketing surveillance is reported hereunder.
Učestalost nuspojava u kliničkim ispitivanjima i istraživanjima nakon stavljanja lijeka na tržište je navedena ispod.
Frequency of adverse reactions is defined using the following convention: very common ( 1/10); common ( 1/100 to  1/10); uncommon ( 1/1,000 to  1/100); rare ( 1/10,000 to
Učestalost nuspojava definirana je pomoću sljedećih kategorija: vrlo česte ( 1/10); česte ( 1/100 i  1/10); manje česte ( 1/1000 i  1/100); rijetke ( 1/10 000 i
Frequency of application
Učestalost primjene
Frequency of ARs
Učestalost nuspojava
Frequency of ARs (MedDRA Preferred Term, PT)
Učestalost nuspojava (MedDRA terminologija, PT (preferirani termin))
Frequency of baseline NS5A resistance-associated variants (RAVs)
Učestalost početnih varijanti proteina NS5A koje su povezane srezistencijom
Frequency of clinically significant exacerbations
Učestalost klinički značajnih egzacerbacija
Frequency of CTCAE grade 3-4
Učestalost nuspojava stupnja 3-4 prema CTCAE
Frequency of doses (hours)/ Duration of therapy (days)
Učestalost doziranja (sati)/trajanje terapije (dani)
Frequency of doses (hours)/Duration of therapy (days)
Učestalost doza (sati)/Trajanje liječenja (dani)
Frequency of doses (hours)/duration of therapy (days)
Učestalost doziranja (sati)/ trajanje terapije (dani)
Frequency of emergence of YMDD mutant HBV and impact on the treatment response
Učestalost pojavljivanja YMDD mutiranog virusa HBV i utjecaj na odgovor na liječenje
Frequency of emergence of YMDD mutant HBV and impact on the treatment response:
Učestalost pojavljivanja YMDD tipa virusa i utjecaj na odgovor na liječenje
Frequency of exacerbations requiring hospitalisations/emergency room visits
Učestalost egzacerbacija koje su zahtijevale hospitalizaciju/posjete hitnoj službi
Frequency of liver function tests
Učestalost testiranja jetrene funkcije
Frequency of occurrence
Učestalost pojave
Frequency of occurrence of adverse reactions
Učestalost nuspojava
Frequency of occurring per patient of adverse drug reactions (ADRs) in clinical trials in 135 previously treated patients with severe haemophilia A
Učestalost pojave nuspojava na lijek po bolesniku u kliničkim ispitivanjima u 135 prethodno liječenih bolesnika s teškom hemofilijom A
Frequency of reaction
Učestalost nuspojave
Frequency of submission
Učestalost podnošenja
Frequency of submission:
Učestalost podnošenja:
Frequency of the adverse reactions is defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Učestalost nuspojava definirana je kao: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
Frequency of these reactions caanot be estimated from available data.
Učestalost tih reakcija ne može se procijeniti iz dostupnih podataka.
Frequency of these reactions cannot be estimated from availabla data.
Učestalost tih reakcija ne može se procijeniti iz dostupnih podataka.
Frequency of these reactions is not known (cannot be estimated from the available data).
Učestalost tih reakcija nije poznata (ne može se procijeniti iz dostupnih podataka).
frequency of voriconazole and
vorikonazola i everolimusa se
Frequency per injection has been evaluated using the following criteria: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Učestalost po injiciranju procijenjena je na osnovi sljedećih kriterija: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Frequency per patient (based on six months of exposure during clinical trials) has been evaluated according to the following convention: common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and very rare (<1/10,000).
Učestalost po bolesniku (na temelju šest mjeseci izloženosti tijekom kliničkih ispitivanja) procijenjena je u skladu sa sljedećom konvencijom: često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100) i vrlo rijetko (<1/10 000).
Frequency rare: Cases of tumour lysis syndrome have been reported in patients treated with Tasigna.
Rijetka učestalost: slučajevi sindroma lize tumora bili su prijavljeni u bolesnika koji su primali terapiju lijekom Tasigna.
Frequency System
Učestalost
Frequency uncommon
Učestalost manje često
Frequency uncommon.
Učestalost manje često.
Frequency unknown (cannot be estimated from the available data): interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing.
Nepoznata učestalost (ne može se procijeniti iz dostupnih podataka): intersticijska bolest pluća (upala pluća koja izaziva kašalj i otežano disanje.
Frequency unknown (cannot be estimated from the available data): interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing.
Nepoznata učestalost (ne može se procjeniti iz dostupnih podataka): intersticijska bolest pluća (upala pluća koja izaziva kašalj i otežano disanje.
Frequency unknown: interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing.
Nepoznata učestalost: intersticijska bolest pluća (upala pluća koja izaziva kašalj i otežano disanje.
Frequency unknown: interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing.
Učestalost nepoznata: intersticijska bolest pluća (zapaljenje pluća koje uzrokuje kašalj i poteškoće s disanjem.
Frequency*
Učestal ost
Frequency*
Učestalost
Frequency, type and severity of adverse reactions in adolescents aged 16-18 years are expected to be the same as in adults.
Očekuje se da je učestalost, vrsta i težina nuspojava u adolescenata i djece u dobi od 16 – 18 godina ista kao i u odraslih.
Frequency, type and severity of adverse reactions in children are assumed to be the same as in adults.
Pretpostavlja se da su učestalost, vrsta i jačina nuspojava u djece jednaki kao u odraslih.
Frequency, type and severity of adverse reactions in children are expected to be similar as in adults.
Očekuje se da će učestalost, vrsta i težina nuspojava u djece biti slične kao i u odraslih.
Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.
Kod djece se očekuje jednaka učestalost, vrsta i težina nuspojava kao i kod odraslih.
Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.
Očekuje se da će učestalost, vrsta i težinu nuspojava u djece biti ista kao u odraslih.
Frequency, type and severity of adverse reactions in children are similar to those observed in adults.
Učestalost, vrsta i intenzitet nuspojava u djece slični su onima zabilježenima u odraslih.
Frequency, type and severity of adverse reactions in children are similar to those reported in adults.
Učestalost, vrsta i težina nuspojava u djece slične su onima zabilježenima u odraslih.
Frequency, type and severity of adverse reactions in children were essentially similar to those in adults.
Učestalost, vrsta i težina nuspojava u djece bile su u biti slične onima u odraslih.
Frequency1
Učestalost1
Frequency:
Učestalost:
Frequency: Adverse Drug Reaction
Učestalost: nuspojava na lijek
Frequency: Adverse reaction
Učestalost: nuspojave
Frequencya
Učestalosta
Frequent antithrombin activity assessments and dosing adjustments may be necessary when starting treatment and just after surgery.
Česte procjene aktivnosti antitrombina i prilagodbe doze možda će biti potrebne na početku liječenja i neposredno nakon operacije.
Frequent bowel movements
pojačana peristaltika crijeva
frequent bowel movements
učestale stolice
Frequent bowel movements
česta pražnjenja crijeva
frequent episodes of hypoglycaemia reduced or absent warning signs of hypoglycaemia
ako imate česte epizode hipoglikemije ako su upozoravajući znakovi hipoglikemije slabiji ili izostaju.
Frequent evaluation of coagulation parameters is important before and during asparaginase treatment.
Prije i tijekom liječenja asparaginazom, važno je učestalo procjenjivati parametre koagulacije.
Frequent loose or liquid bowel movements
Česta meka ili tekuća stolica
Frequent loose or liquid bowel movements
Česta mekana ili tekuća stolica
Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co- administration with posaconazole.
Tijekom istodobne primjene s posakonazolom preporučuje se učestalo nadziranje bolesnika zbog mogućih nuspojava i reakcija toksičnosti povezanih s antiretrovirusnim lijekovima koji su supstrati enzima CYP3A4.
Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended when co-administered with voriconazole since methadone levels increased following co- administration of voriconazole.
Budući da je nakon istodobne primjene s vorikonazolom došlo do povećanja razine metadona, kod istodobne primjene metadona i vorikonazola preporučuju se česte kontrole zbog mogućih nuspojava i toksičnih učinaka metadona, uključujući produljenje QTc-intervala.
Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended.
Možda će biti potrebne česte kontrole zbog mogućih nuspojava povezanih s opijatima.
Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended.
Preporučuju se česte kontrole zbog mogućih nuspojava i toksičnosti vezanih uz metadon, uključujući produljenje QT- intervala.
Frequent monitoring for adverse reactions and toxicity related to NSAIDs is recommended.
Preporučuju se česte kontrole zbog mogućih nuspojava i toksičnosti povezane s NSAIL- om.
Frequent monitoring for adverse reactions and toxicity related to NSAIDs is recommended.
Preporučuju se česte kontrole zbog mogućih nuspojava NSAR
Frequent monitoring for opiate-
Opijati dugog djelovanja
Frequent monitoring for opiate- associated adverse reactions may be necessary (see section 4.5).
Možda će biti potrebne česte kontrole zbog mogućih nuspojava povezanih s opijatima (vidjeti dio 4.5).
Frequent monitoring of tacrolimus whole
Preporučuje se učestalo praćenje koncentracija
frequent or loose bowel movements (diarrhoea)
učestale ili mekane stolice (proljev)
frequent or loose bowel movements (diarrhoea)
učestale ili rijetke stolice (proljev)
frequent or urgent need to urinate
česta ili hitna potreba za mokrenjem
Frequent re-examination of the dog will enhance the establishment of an appropriate diuretic dose.
Česti kontrolni pregledi psa poboljšat će utvrđivanje odgovarajuće doze diuretika.
frequent urination
učestalo mokrenje
frequent urination
često mokrenje
frequent urination, difficulty with holding your urine or urine leakage
učestalo mokrenje, poteškoće sa zadržavanjem urina ili nevoljno istjecanje urina
frequent urination, passing more urine than normal, presence of sugar or blood in urine,
učestalo mokrenje, mokrenje više nego uobičajeno, prisutnost glukoze ili krvi u mokraći,
frequent urination, passing more urine than normal, presence of sugar or blood in urine,
često mokrenje, veća količina mokraće nego obično, prisutnost šećera ili krvi u mokraći
frequent urination, urinary urgency (must hurry to pass urine), difficult or painful urination, urination at night, impaired renal function, incontinence
učestalo mokrenje, urgentno mokrenje (neodgodiva potreba za mokrenjem), teškoće s mokrenjem ili bolno mokrenje, noćno mokrenje, oštećena bubrežna funkcija, nemogućnost zadržavanja mokraće (inkontinencija)
Frequent urination.
učestalo mokrenje.
Frequent urination;
Često mokrenje;
frequent urine output palpitations (sensation of rapid heart beat)
često mokrenje palpitacije (osjećaj ubrzanog kucanja srca).
frequent urine output, abnormal urine colour
često mokrenje, promijenjena boja mokraće
FREQUENTLY ASKED QUESTIONS
ČESTA PITANJA
Frequently Asked Questions about Injecting Your Dose
Česta pitanja o injiciranju doze
Frequently Asked Questions about Preparing KwikPen
Česta pitanja o pripremi KwikPena
Frequently Asked Questions about Priming
Česta pitanja o provjeri protoka inzulina
Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines.
Lijekovi koji su često istodobno primijenjivani uključivali su: paracetamol, nesteroidne protuupalne lijekove (kao što su acetilsalicilatna kiselina, ibuprofen i naproksen), oralne antibiotike, H1-antagoniste, H2-antagoniste i benzodiazepine.
Frequently occurring adverse events:
Česte nuspojave:
frequently passing wind (flatulence)
učestali vjetrovi (nadutost)
Frequently reported non-haematological effects were gastrointestinal such as nausea (52 %), vomiting (32 %), and diarrhoea (18 %), constipation (9 %) and mucositis (14 %).
Često prijavljene nehematološke nuspojave bile su gastrointestinalne poput mučnine (52%), povraćanja (32%) i proljeva (18%), konstipacije (9%) i mukozitisa (14%).
Fresenius Kabi Austria GmbH Tel: +43 316 249 0
Fresenius Kabi Italia S.r.l Tel: + 39 045 6649311
Fresenius Kabi Baltics UAB Tel: +370 52609169
Fresenius Kabi Polska Sp. z o.o.
Fresenius Kabi Italia S.r.l Tel: + 39 045 6649311
Fresenius Kabi Italia S.r.l
Fresenius Kabi Pharma Portugal, Lda Tel: + 351 21 424 1280
KBM Pharma SIA Tel: +371 67103113
Fresenius Kabi Polska Sp. z o.o.
Fresenius Kabi Hellas A.E
Fresh blood in stool or black tarry stool for >2 days or frank haemorrhage or blood clots in stool
Svježa krv u stolici ili crna katranasta stolica > 2 dana ili očito krvarenje ili krvni ugrušci u stolici
Freshly washed, but dry and cool (wait a few minutes after taking a hot bath or shower).
upravo oprano, ali osušeno i ohlađeno (pričekajte nekoliko minuta nakon vruće kupke ili tuša).
Fri.
pet.
Frimley
Frimley, Camberley,
Frimley Business Park
Frimley Business Park,
Frimley Business Park Frimley
Frimley Business Park, Frimley, Camberley,
Frimley Business Park, Frimley,
Frimley Business Park Frimley
Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, United Kingdom
Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR,Velika Britanija
Frimley, Camberley, Surrey GU16 7SR United Kingdom.
Frimley, Camberley, Surrey, GU16 7SR Velika Britanija
Frimley, Camberley, Surrey GU16 7SR United Kingdom.
Frimley, Camberley, Surrey, GU16 7SR Velika Britanija.
from 1 to 6 years: 25 mg twice daily
od 1 do 6 godina: 25 mg dva puta dnevno
From 15 years and above
15 ili više godina
From 18 years onwards: you will receive one dose of Adjupanrix.
Od 18 godina naviše: primit ćete jednu dozu cjepiva Adjupanrix.
From 18 years onwards: you will receive two doses of Adjupanrix.
Od 18 godina naviše: primit ćete dvije doze cjepiva Adjupanrix.
From 18 years onwards: you will receive two doses of Prepandrix.
Osobe starije od 18 godina: primit ćete dvije doze cjepiva Prepandrix.
From 33 weeks to 18 years
Od 33 tjedna do 18 godina
From 50 kg(2)
Iznad 50 kg(2)
from 6 to 16 years if bodyweight under 57 kg: 25 mg three times daily from 16 years or if bodyweight above 57 kg: 50 mg three times daily.
od 6 do 16 godina ako je tjelesna težina ispod 57 kg: 25 mg tri puta dnevno od 16 godina ili ako je tjelesna težina iznad 57 kg: 50 mg tri puta dnevno.
From 6 weeks to 32 weeks
Od 6 tjedana do 32 tjedna
from 60 mg to 130 mg
rasponu od 60 mg do
From 8 – 14 days old: 0.25 ml subcutaneously.
Od 8 - 14 dana starosti: 0,25 ml potkožno.
From 8 – 14 days old: administer 0.25 ml subcutaneously.
Od 8 - 14 dana starosti: 0,25 ml primijeniti potkožno.
From 80 years onwards: you may receive two double injections of Adjupanrix.
Od 80 godina naviše: možda ćete primiti dvije dvostruke injekcije cjepiva Adjupanrix.
From 80 years onwards: you may receive two double injections of Prepandrix.
Osobe starije od 80 godina: možda ćete primiti dvije dvostruke injekcije cjepiva Prepandrix.
From a 100 ml infusion bag or bottle (typically, an infusion volume of 100 ml will be appropriate for most patients and doses, but total infusion volume ranging from 50 ml to 250 ml may be used), withdraw a volume of sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection equal to the volume (ml equals total dose in mg divided by 25) of the reconstituted belatacept solution required to provide the dose and discard it.
Iz 100 ml infuzijske vrećice ili boce (volumen infuzije od 100 ml će, u pravilu, biti prikladan za većinu bolesnika i doza, ali može se primijeniti i ukupni volumen infuzije u rasponu od 50 ml do 250 ml), izvucite volumen 9 mg/ml (0,9%) otopine za injekciju natrijevog klorida ili 5% otopine glukoze za injekciju jednak volumenu (ml je jednak ukupnoj dozi u mg podijeljenoj s 25) pripremljene otopine belatacepta potrebne da bi se dala doza i bacite ga.
From a 100 ml infusion bag or bottle (typically, an infusion volume of 100 ml will be appropriate for most patients and doses, but total infusion volume ranging from 50 ml to 250 ml may be used), withdraw a volume of sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection equal to the volume (ml equals total dose in mg divided by 25) of the reconstituted NULOJIX solution required to provide the dose and discard it.
Iz 100 ml infuzijske vrećice ili boce (volumen infuzije od 100 ml će, u pravilu, biti prikladan za većinu bolesnika i doza, ali može se primijeniti i ukupni volumen infuzije u rasponu od 50 ml do 250 ml), izvucite volumen 9 mg/ml (0,9%) otopine za injekciju natrijevog klorida od ili 5% otopine glukoze za injekciju jednak volumenu (ml je jednak ukupnoj dozi u mg podijeljenoj s 25) pripremljene otopine belatacepta potrebne da bi se dala doza i bacite ga.
From a 100 mL infusion bag or bottle, withdraw a volume of sodium chloride 9 mg/mL (0.9%) solution for injection equal to the volume of the reconstituted vials.
Iz infuzijske vrećice ili boce od 100 ml izvucite volumen otopine natrijevog klorida za injekciju od 9 mg/ml (0,9%) jednak volumenu rekonstituiranih bočica.
From a 250 ml infusion bag or bottle of sodium chloride 9 mg/ml (0.9%), sodium chloride 4.5 mg/ml (0.45%), or Lactated Ringer’s solution for injection, withdraw and discard a volume equal to the volume of the reconstituted Benlysta solution required for the patient’s dose.
Iz infuzijske vrećice ili boce od 250 ml 0,9%-tne (9 mg/ml) otopine natrijevog klorida, 0,45%-tne (4,5 mg/ml) otopine natrijevog klorida ili otopine Ringerovog laktata za injekcije, izvucite i odbacite volumen jednak volumenu rekonstituirane otopine lijeka Benlysta potrebne za bolesnikovu dozu.
From a baseline mean absolute lymphocyte count of approximately 2,200 cells/μl, a mean decrease of approximately 100 cells/μl relative to placebo was observed in the placebo-controlled pooled analysis.
U analizi objedinjenih podataka iz placebom kontroliranih ispitivanja opaženo je srednje smanjenje od približno 100 stanica/μl, u odnosu na placebo, od početnog srednjeg ukupnog broja limfocita od približno 2200 stanica/µl..
From a baseline mean absolute lymphocyte count of approximately 2,200 cells/μl, a mean decrease of approximately 100 cells/μl relative to placebo was observed in theplacebo-controlled pooled analysis.
U analizi objedinjenih podataka iz placebom kontroliranih ispitivanja opaženo je srednje smanjenje od približno 100 stanica/μl, u odnosu na placebo, od početnog srednjeg ukupnog broja limfocita od približno 2200 stanica/µl.